Sofosbuvir L-alanitate (Mixture of Diasteriomers)

Sofosbuvir L-alaninate (mixture of diastereomers) is a chemical compound used in the treatment of hepatitis C virus (HCV). It is a prodrug of sofosbuvir, which is a nucleotide analog inhibitor of HCV polymerase NS5B. Sofosbuvir L-alaninate (mixture of diastereomers) is converted into sofosbuvir in the liver, which then inhibits the replication of the HCV virus in the body. Sofosbuvir L-alaninate (mixture of diastereomers) is administered orally in the form of tablets. The recommended dosage is one tablet (400 mg) once a day, taken with or without food. The treatment duration and dosage may vary depending on the severity of the infection and other factors. The chemical name of Sofosbuvir L-alaninate (mixture of diastereomers) is (2S)-2-[[[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl]methoxy-phenoxy-phosphoryl]amino]propanoic acid. Its molecular formula is C22H29FN3O9P and its molecular weight is 529.45 g/mol. Sofosbuvir L-alaninate (mixture of diastereomers) is generally well-tolerated, but may cause some side effects such as headache, fatigue, nausea, and diarrhea. It is not recommended for use in patients with severe renal impairment or end-stage renal disease. It may also interact with other medications, so it is important to inform your doctor about any other medications you are taking before starting this treatment.